PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
22.78%
Cost growth of 22.78% while RVPH maintains flat costs. Bruce Berkowitz would investigate efficiency gap.
-30.37%
Gross profit decline while RVPH shows 0.00% growth. Joel Greenblatt would examine competitive position.
-30.37%
Margin decline while RVPH shows 0.00% expansion. Joel Greenblatt would examine competitive position.
45.24%
R&D growth while RVPH reduces spending. John Neff would investigate strategic advantage.
-4.95%
G&A reduction while RVPH shows 25.06% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
24.69%
Operating expenses growth while RVPH reduces costs. John Neff would investigate differences.
24.69%
Total costs growth while RVPH reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
22.78%
D&A growth less than half of RVPH's 115.21%. David Dodd would verify if efficiency is sustainable.
-24.88%
EBITDA decline while RVPH shows 37.46% growth. Joel Greenblatt would examine position.
-24.88%
EBITDA margin decline while RVPH shows 0.00% growth. Joel Greenblatt would examine position.
-24.83%
Operating income decline while RVPH shows 35.45% growth. Joel Greenblatt would examine position.
-24.83%
Operating margin decline while RVPH shows 0.00% growth. Joel Greenblatt would examine position.
291.57%
Other expenses growth while RVPH reduces costs. John Neff would investigate differences.
-21.98%
Pre-tax income decline while RVPH shows 34.13% growth. Joel Greenblatt would examine position.
-21.98%
Pre-tax margin decline while RVPH shows 0.00% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-17.79%
Net income decline while RVPH shows 34.18% growth. Joel Greenblatt would examine position.
-17.79%
Net margin decline while RVPH shows 0.00% growth. Joel Greenblatt would examine position.
-12.12%
EPS decline while RVPH shows 37.93% growth. Joel Greenblatt would examine position.
-9.09%
Diluted EPS decline while RVPH shows 37.93% growth. Joel Greenblatt would examine position.
5.06%
Share count reduction below 50% of RVPH's 4.35%. Michael Burry would check for concerns.
6.04%
Diluted share reduction below 50% of RVPH's 4.35%. Michael Burry would check for concerns.